

Fax Page 1 To:

Yakima Health District

(509) 381-3526 (Confidential FAX line)

CONFIDENTIAL SEXUALLY TRANSMITTED INFECTION CASE REPORT
Report STIs within 3 work days (WAC 246-101-101/301)

Adapted from WA DOH Form 347-102

PATIENT INFO	RMATION													
LAST NAME			FIRST NAME			MIDDLE NA	MIDDLE NAME			DATE OF BIRTH				
										мо		DAY		YR
ADDRESS (Unhoused or unstably housed in the			n the past	past 3 months) CITY							STATE		ZIP COD	E
TELEPHONE		EMAIL		EN	NGLI:	SH SPEAKIN	IG? ☐ Yes ☐	No *	instruction pg. 3	s on D	IAGNOSI	S DA	TE	
()				Pr	refer	red Langua	ge (Code*: L _			M	0	DAY	<i>r</i>	YR
SEX ASSIGNED	GENDER IDENT	TITY	1	ETHNICIT	Y		RACE CATEG	ORY (check al	l that a	apply)*:			structions on page 3
AT BIRTH			Mile				☐ White	☐ White ☐ Asian ☐ Black ☐ Other						
		☐ Transgende				nic	☐ Americar	ı Indiai	n / Alasl					
☐ Intersex				☐ Refuse			☐ Native Ha	awaiia	n / Othe	r Pacif	ic Islande	r	☐ Refus	ed
Refused Genderqueer Enterused			'	EXTENDED RACE CO				CODE(S	DE(S)*: R R R R					
CURRENTLY	REASON FOR EX	XAM (check one):	GENDE	R OF SEX	PAR	TNERS (che	k all that apply): HI	V STATU	IS	*Submit HIV	//AIDS C	Case Report	CURRENTLY
PREGNANT? Exposed to I				_ 0						as positive			ON PrEP?	
☐ Yes	Symptomatic	· —		emale				IIV diagnosis at this visit*			Yes			
☐ No ☐ Routine Exan☐ Unk. ☐ NA		. (,		onbinary /			I _ ~ ~			tive HIV test at this visit No ot test (unknown status) NA			□ No □ NA	
DIAGNOSIS - D	DISFASE]										,	
GONORRHEA (I									S۱	'PHILI	S			
DIAGNOSIS (che	eck one)	SITES (all that a	pply): 1	TREATMENT (check all prescribed):				ST	STAGE (check one):					
Asymptomati		☐ Cervix		☐ Ceftriaxone: ☐ 250 mg ☐ 500 mg ☐ 1 g					☐ Primary (Chancre, etc.)					
	, Uncomplicated	Urethra		☐ Cefixime: ☐ 400 mg ☐ 800 mg					☐ Secondary (Rash, etc.) ☐ Early Latent (< 1 year)					
☐ Pelvic Inflammatory Disease☐ Ophthalmia				☐ Azithromycin: ☐ 1 g ☐ 2 g ☐ Doxycycline: ☐ 100 mg BID x 7 days					Unknown Duration or Late					
☐ Disseminated		☐ Pharynx [☐ Gentamicin: ☐ 240 mg					☐ Congenital					
☐ Other Compli	cations:	☐ Vagina ☐		☐ Gemifloxacin: ☐ 320 mg				М	MANIFESTATIONS (check all that apply):					
Data Tastad:		□ Othor		U Other:				- _	☐ Neurologic ☐ Otic ☐ Ocular ☐ Tertiary					
Date Tested:	h confirmed)	!	<u> </u>	Date Preso	Prescribed:					TDE ATRICALLY (should now a)				
CHLAMYDIA (lab confirmed) DIAGNOSIS (check one)		SITES (all that apply):		TREATMENT (check all prescribed):					TREATMENT (check one): Bicillin L - A: □ 2.4 MU IM x 1					
Asymptomatic		☐ Cervix		☐ Azithromycin: ☐ 1 g					□ 2.4 MU IM x 3					
Symptomatic, Uncomplicated				☐ Doxycycline: ☐ 100 mg BID x 7 days			Do	Doxycycline: 100 mg BID x 14 days						
☐ Pelvic Inflammatory Disease☐ Ophthalmia		☐ Urine		☐ Levofloxacin: ☐ 500 mg daily x 7 days				☐ 100 mg BID x 28 days						
☐ Opnthalmia ☐ Other Complications:		☐ Rectum ☐ Pharynx		Other:				Benzathine 50,000 units/kg IM x 1						
		☐ Vagina						PO	PCN-G: 50,000 units/kg If			g IM x 3		
☐ Ocula		☐ Ocular				I.				Aqueous 18-24 MU/day IV			IV	
Date Tested:		Other:		Date Prescribed: OTHER DISEASES				_	Crystalline for 10-14 days Penicillin G:					
HERPES SIMPLE DIAGNOSIS	:X	LABORATORY CO	NFIRMAT							her: _				
☐ Genital (initial infection only)				ATION Chancroid Granuloma Inguina			nale							
☐ Neonatal ☐ No			Lymphogranuloma Venereum						Date Prescribed:					
PARTNER TREATMENT PLAN (check one or more options)														
Providers should manage partner treatment by either treating partners in-person or by prescribing medication for patients to give to their sex partners (see side 2 for additional information).														
for additional information). ☐ In-person evaluation - Number of partners treated following medical evaluation: ☐ In-person evaluation - Number of partners treated following medical evaluation:														
Patient-delivered treatment* - Number of partners for whom provider prescribed or provided expedited partner therapy (EPT) medication pack to be delivered by the patient to their partner(s): *Patient-delivered treatment is not recommended for men who have sex with men or patients with syphilis														
REPORTING CLINIC INFORMATION														
DATE	FACILITY NAME DIAGNOSING CLINICIAN													
ADDRESS						CITY				STATE		ZI	IP	
PERSON COMPLETING FORM				TELEP	HON ۱	IE			EMAIL					

PARTNER MANAGEMENT PLAN INSTRUCTIONS

Gonorrhea or Chlamydia Infection: Partner Treatment

All partners should be treated as if they are infected.

The Washington State Department of Health strongly encourages providers to take responsibility to ensure partner treatment for heterosexuals, by examining and treating all patient's sex partners from the previous 60 days.

If an examination is not possible, providers should offer medication for all sex partners whom patients are able to contact.

Yakima Health District may be able to provide free medication to your patient to give their partner(s), if resources permit. Please contact your local health jurisdiction to report cases and inquire about partner management resources, possibly including EPT medications.

Yakima Health District recommends you refer all **MSM patients** and **all patients with syphilis or newly diagnosed HIV** to the health department for help notifying partners to ensure that partners receive medication; the opportunity to test for HIV, syphilis, gonorrhea, and chlamydia; and evaluation for HIV Pre-Exposure Prophylaxis (PrEP). Please inform the patient that the health department will contact them to assist with partner notification.

Although the Health Department requests that you refer patients with these risks to us, we also ask that you make every effort to help patients assure that their partners are treated.

Complete the partner management plan on the Confidential Sexually Transmitted Infection Case Report FAX form to define a partner management plan.

For copies of this case report or questions on how to fill it out, call the Yakima Health District: (509) 249-6541.

Other STIs: Partner Treatment

All patients with infectious syphilis, chancroid, LGV, or granuloma inguinale are routinely contacted by public health staff. Patients diagnosed with genital herpes should be advised to notify their sex partners and should be informed that their partners should contact their provider for testing. Per CDC treatment guidelines, sex partners of patients who are diagnosed with early syphilis (primary, secondary, or early latent) and may be incubating disease should be treated regardless of test results. Alternative treatment for penicillin allergy among non-pregnant patients, such as an appropriate dosage of doxycycline, can also be found in the guidelines.

RECOMMENDED REGIMENS FOR ANTIMICROBIALS LISTED ON REPORTS*

GONORRHEA -- Uncomplicated

Ceftriaxone 500 mg IM as a single dose for persons weighing < 150 kg (330 lbs), or 1 g IM as a single dose for persons weighing > 150 kg (330 lbs) †

Alternatives for uncomplicated infections of the cervix, urethra, or rectum: ‡

Gentamicin 240 mg IM as a single dose PLUS azithromycin 2 g PO as a single dose $\bf OR$ Cefixime 800 mg orally as a single dose †

- † If treating with ceftriaxone or cefixime, and chlamydia infection has not been excluded, providers should treat for chlamydia with doxycycline 100 mg PO BID for 7 days. During pregnancy, azithromycin 1 g PO as a single dose is recommended to treat chlamydia.
- [‡] Ceftriaxone is the only recommended treatment for pharyngeal gonorrhea. Consult an infectious disease provider or other STI expert for assistance if alternative treatment is required.

CHLAMYDIA -- Uncomplicated

Doxycycline 100 mg PO BID for 7 days **OR** Azithromycin 1g PO as a single dose

Alternatives:

Erythromycin (base) 500 mg PO QID for 7 days OR

Ethylsuccinate 800 mg PO QID for 7 days OR

Ofloxacin 300 mg PO BID for 7 days OR

Levofloxacin 500 mg PO for 7 days

SYPHILIS -- PRIMARY, SECONDARY, OR EARLY LATENT (<1 YEAR)

Benzathine penicillin G 2.4 million units IM in a single dose

SYPHILIS -- LATE OR UNKNOWN DURATION

Benzathine penicillin G 2.4 million units IM for 3 doses at 1 week intervals

DOH 347-102, updated 12/14/2022. For persons with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).

^{*} Refer to "STD Diagnostic and Treatment Guidelines" or the Centers for Disease Control and Prevention's (CDC's) website (https://www.cdc.gov/std/treatment/default.htm) for further information on treating pregnant patients, infections of the pharynx, patients with allergies, treatment of infants, and other details.

List of Preferred Languages:

Instructions: Complete the Preferred Language section if the patient's preferred language is not English. Patient's preferred language shall be identified by the patient and reported using one of the below categories.

Language Identity Codes:

(L18) Karen	(L35) Sign languages
(L19) Khmer/Cambodian	(L36) Somali
(L20) Kinyarwanda	(L37) Spanish/Castilian
(L21) Korean	(L38) Swahili/Kiswahili
(L22) Kosraean	(L39) Tagalog
(L23) Lao	(L40) Tamil
(L24) Mandarin	(L41) Telugu
(L25) Marshallese	(L42) Thai
(L26) Mixteco	(L43) Tigrinya
(L27) Nepali	(L44) Ukrainian
(L28) Oromo	(L45) Urdu
(L29) Panjabi/Punjabi	(L46) Vietnamese
(L30) Pashto	(L77) Other language
(L31) Portuguese	(L88) Patient declined to respond
(L32) Romanian/Rumanian	(L99) Unknown
	(L19) Khmer/Cambodian (L20) Kinyarwanda (L21) Korean (L22) Kosraean (L23) Lao (L24) Mandarin (L25) Marshallese (L26) Mixteco (L27) Nepali (L28) Oromo (L29) Panjabi/Punjabi (L30) Pashto (L31) Portuguese

(L33) Russian

(L34) Samoan

Race Category and Identity Instructions:

Instructions: The patient's race may either be reported in the general Race Category section or the Extended Race section on page 1 of the case report. When completing the Extended Race section, please report using the codes provided in the list below. If the patient self-identifies as more than one race, each race code shall be reported within the extended race section. Unknown race can be documented within either one of the race sections.

Extended Race Codes:

(L16) Hmong

(L17) Japanese

(R01) Afghan	(R22) Fijian	(R43) Mexican/Mexican American	(R64) Tongan
(R02) Afro-Caribbean	(R23) Filipino	(R44) Middle Eastern	(R65) Ugandan
(R03) Alaska Native	(R24) First Nations	(R45) Mien	(R66) Ukrainian
(R04) American Indian	(R25) Guamanian or Chamorro	(R46) Moroccan	(R67) Vietnamese
(R05) Arab	(R26) Hmong/Mong	(R47) Native Hawaiian	(R68) White
(R06) Asian	(R27) Indigenous-Latina/o/x	(R48) Nepalese	(R69) Yemeni
(R07) Asian Indian	(R28) Indonesian	(R49) North African	(R77) Other race
(R08) Bamar/Burman/Burmese	(R29) Iranian	(R50) Oromo	(R99) Unknown
(R09) Bangladeshi	(R30) Iraqi	(R51) Pacific Islander	
(R10) Bhutanese	(R31) Japanese	(R52) Pakistani	
(R11) Black or African American	(R32) Jordanian	(R53) Puerto Rican	
(R12) Central American	(R33) Karen	(R54) Romanian/Rumanian	
(R13) Cham	(R34) Kenyan	(R55) Russian	
(R14) Chicana/o or Chicanx	(R35) Khmer/Cambodian	(R56) Samoan	
(R15) Chinese	(R36) Korean	(R57) Saudi Arabian	
(R16) Congolese	(R37) Kuwaiti	(R58) Somali	
(R17) Cuban	(R38) Lao	(R59) South African	
(R18) Dominican	(R39) Lebanese	(R60) South American	
(R19) Egyptian	(R40) Malaysian	(R61) Syrian	
(R20) Eritrean	(R41) Marshallese	(R62) Taiwanese	
(R21) Ethiopian	(R42) Mestizo	(R63) Thai	